Mylan Pharmaceuticals is a finished-dose manufacturer based in United States. It appears in 1,610 regulatory filings across 19 regulators, without an active US DMF or CEP on file. Its filings concentrate with SWISSMEDIC (CH), AIFA (IT) and US FDA. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 18 August 2023 as NAI. Customs aggregates show $64K of exports covering 1 molecule to 1 destination in 2024.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Steinhausen, Switzerland | Not on file |
| Steinhausen, Switzerland | Not on file |
| CASABLANCA, Morocco | Not on file |
| SAN CARLOS, United States | Not on file |
| Morgantown, United States | 1110315 |
| Regulator | Filings | GMP certificates |
|---|---|---|
| SWISSMEDIC (CH) | 437 | None |
| AIFA (IT) | 305 | None |
| US FDA | 289 | 1 |
| FAMHP (BE) | 238 | None |
| MEDSAFE (NZ) | 153 | None |
| INFARMED (PT) | 38 | None |
| MFDS (Korea) | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2024 | Not reported | $64K | 1 |
| 2023 | Not reported | $908K | 5 |
| 2022 | Not reported | $3.3M | 14 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Mylan Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for free